What Semaglutide Is: The GLP-1 Receptor Agonist Behind Ozempic, Wegovy and Rybelsus
Semaglutide is an engineered analogue of the gut hormone GLP-1, sold in the United States under several brand names. This profile covers what the molecule is, how it works, the major human trials, and what current FDA labels say about approved uses and risks.
By the GLP Semaglutide editorial team · Last updated November 16, 2026

Semaglutide is a laboratory-modified version of glucagon-like peptide-1, a hormone the intestine already makes after a meal. In the United States it is the active ingredient in once-weekly injections sold as Ozempic and Wegovy and in once-daily oral tablets sold as Rybelsus and, in more recent labeling, as Ozempic tablets and Wegovy tablets.
What the molecule is
According to the FDA prescribing information for Ozempic, semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. The peptide backbone is produced by yeast fermentation. The labels describe three design changes that distinguish it from the native hormone: a modification at position 8 that helps it resist breakdown by the enzyme dipeptidyl-peptidase 4 (DPP-4); attachment of a C18 fatty di-acid, via a hydrophilic spacer, at lysine 26 to promote binding to albumin; and a change at position 34 so that only one fatty-acid chain is attached. A 2019 review in Frontiers in Endocrinology, archived on PMC, places that chemistry in the same line of work that produced the once-daily analogue liraglutide, and describes semaglutide as the once-weekly successor selected from that effort.
How it works
The labels state that semaglutide selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. In type 2 diabetes, that activation is described as stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in early postprandial gastric emptying. The Wegovy label also notes that GLP-1 regulates appetite and caloric intake. The exact mechanisms for cardiovascular-risk reduction, and for the kidney-related indication on the Ozempic label, have not been established. The Ozempic label gives an elimination half-life of approximately one week, attributed mainly to albumin binding, and says the drug remains in the circulation for about five weeks after the last dose.
What the major human trials show
In SUSTAIN 6, a cardiovascular-outcomes trial in adults with type 2 diabetes and high cardiovascular risk, the Ozempic label reports that a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke occurred in 6.6% of patients assigned to semaglutide and 8.9% assigned to placebo (hazard ratio 0.74; 95% confidence interval, 0.58 to 0.95) over a median 2.1 years. In the FLOW trial (ClinicalTrials.gov NCT03819153), in adults with type 2 diabetes and chronic kidney disease, the same label reports that semaglutide reduced a composite of a sustained eGFR decline of at least 50%, kidney failure, and cardiovascular or renal death (hazard ratio 0.76; 95% CI, 0.66 to 0.88). For weight management, Wegovy Study 2 (NCT03548935) enrolled 1,961 adults with obesity, or overweight plus a weight-related comorbid condition, and without type 2 diabetes; after 68 weeks, mean body weight changed by -14.9% with the weekly injection versus -2.4% with placebo. In Study 1 (NCT03574597), 17,604 adults aged 45 or older with overweight or obesity and established cardiovascular disease, but without diabetes, were followed for a median 41.8 months; the label reports that the weekly injection reduced first major adverse cardiovascular events (hazard ratio 0.80; 95% CI, 0.72 to 0.90).
What the labels approve, and what they warn about
Semaglutide was first approved in the United States in 2017. Current Ozempic labeling covers use, with diet and exercise, to improve glycemic control in adults with type 2 diabetes; to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, for cardiovascular-risk reduction in adults with established cardiovascular disease and obesity or overweight; for long-term weight reduction in adults and in pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and, under accelerated approval that may depend on a confirmatory trial, for noncirrhotic MASH (formerly NASH) with moderate to advanced (F2 to F3) liver fibrosis in adults. Wegovy tablets carry the adult weight-management and cardiovascular-risk-reduction indications, but not the pediatric or MASH indications listed for the injection.
Both labels carry a boxed warning that semaglutide causes thyroid C-cell tumors in rodents, that human relevance has not been determined, and that the products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Other warnings include acute pancreatitis, diabetic retinopathy complications, acute kidney injury related to volume depletion, severe gastrointestinal adverse reactions, acute gallbladder disease, serious hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation. The most common adverse reactions include nausea, vomiting, diarrhea, abdominal pain, and constipation. The labels also advise against combining semaglutide-containing products, and the Ozempic label tells clinicians to stop the drug in women at least two months before a planned pregnancy. Questions about whether a specific product is appropriate belong with a licensed clinician and the official prescribing information.
Primary sources